Education
About Us
Working with TipRanks
Follow Us
RedHill Biopharma Ltd (RDHL)
:RDHL
RDHL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.06 - $9.00
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.97M
Market Cap
$6.06M
Enterprise Value$685.79K
Total Cash (Recent Filing)$7.01M
Total Debt (Recent Filing)$2.28M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding3,329,857
10 Day Avg. Volume5,831,654
30 Day Avg. Volume1,971,592
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.27
Price to Sales (P/S)1.90
P/FCF Ratio-1.63
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda0.01
Forecast
1Y Price Target
$2.00Price Target Upside9.29% Upside
Rating ConsensusHold
Number of Analyst Covering0
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma Ltd’s price range in the past 12 months?
RedHill Biopharma Ltd lowest stock price was $1.06 and its highest was $9.00 in the past 12 months.
What is RedHill Biopharma Ltd’s market cap?
RedHill Biopharma Ltd’s market cap is $6.06M.
When is RedHill Biopharma Ltd’s upcoming earnings report date?
RedHill Biopharma Ltd’s upcoming earnings report date is Mar 12, 2026 which is in 152 days.
How were RedHill Biopharma Ltd’s earnings last quarter?
RedHill Biopharma Ltd released its earnings results on Sep 05, 2025. The company reported -$2.318 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.318.
Is RedHill Biopharma Ltd overvalued?
According to Wall Street analysts RedHill Biopharma Ltd’s price is currently Undervalued.
Does RedHill Biopharma Ltd pay dividends?
RedHill Biopharma Ltd does not currently pay dividends.
What is RedHill Biopharma Ltd’s EPS estimate?
RedHill Biopharma Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma Ltd have?
RedHill Biopharma Ltd has 3,329,857 shares outstanding.
What happened to RedHill Biopharma Ltd’s price movement after its last earnings report?
RedHill Biopharma Ltd reported an EPS of -$2.318 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of RedHill Biopharma Ltd?
Currently, no hedge funds are holding shares in RDHL
Company Description
RedHill Biopharma Ltd
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on creating oral drug formulations that address unmet medical needs. RedHill's core products include therapies targeting conditions such as peptic ulcers, inflammatory bowel disease, and other gastrointestinal disorders, as well as oncology treatments.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---